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A B S T R A C T
Objectives: Gemcitabine/carboplatin treatment is known to cause severe adverse drug reactions which can lead
to the need for reduction or cessation of chemotherapy. It would be beneficial to identify patients at risk of
severe hematological toxicity in advance before treatment start. This study aims to identify genetic markers for
gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients.
Material and methods: Whole-exome sequencing was performed on 215 patients. Association analysis was per-
formed on single-nucleotide variants (SNVs) and genes, and the validation was based on an independent
genome-wide association study (GWAS). Based on the association and validation analyses the genetic variants
were then selected for and used in weighted genetic risk score (wGRS) prediction models for leukopenia and
neutropenia.
Results: Association analysis identified 50 and 111 SNVs, and 12 and 20 genes, for leukopenia and neutropenia,
respectively. Of these SNVS 20 and 19 were partially validated for leukopenia and neutropenia, respectively. The
genes SVIL (p = 2.48E-06) and EFCAB2 (p = 4.63E-06) were significantly associated with leukopenia contain
the partially validated SNVs rs3740003, rs10160013, rs1547169, rs10927386 and rs10927387. The wGRS
prediction models showed significantly different risk scores for high and low toxicity patients.
Conclusion: We have identified and partially validated genetic biomarkers in SNVs and genes correlated to
gemcitabine/carboplatin-induced leukopenia and neutropenia and created wGRS models for predicting the risk
of chemotherapy-induced hematological toxicity. These results provide a strong foundation for further studies of
chemotherapy-induced toxicity.
1. Introduction
Lung cancer is the second most common cancer in the United States
with a 5-year relative survival rate of only 18 % [1]. A widely used non-
small cell lung cancer (NSCLC) chemotherapy treatment is gemcitabine
in combination with carboplatin which is also used in the treatment of
other solid tumors such as bladder, ovarian and breast cancer. Gemci-
tabine/carboplatin treatment is known to cause severe toxicity that can
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lead to the need for postponed treatment, reduced doses and in some
cases even discontinuation of treatment [2].
Hematological toxicities, such as leukopenia and neutropenia, are
common adverse drug reactions (ADRs) induced by gemcitabine/car-
boplatin [3,4]. The large variation in toxicity can cause some patients to
display no or moderate symptoms while others experience severe ADRs
or even death. Severe ADRs of grade 3–4 according to the common
terminology criteria for adverse events (CTCAE) have been reported in
20–70 % of patients in clinical studies [2,5–8].
The underlying mechanisms for induced ADRs in patients treated
with chemotherapy are to date not fully understood. Efforts have been
made to find ways to predict hematological toxicity in chemotherapy
treatment using candidate gene approaches and genome-wide associa-
tion studies (GWAS) [9–14]. Present GWAS have either focused on one
therapy towards mixed tumor types or mixed therapies against one
tumor type and are mainly of Asian origin.
The aim of this study is to gain a better understanding of the genetic
variability affecting chemotherapy-induced leukopenia and neu-
tropenia in patients diagnosed with NSCLC undergoing gemcitabine/
carboplatin treatment. Furthermore, the goal is to identify toxicity as-
sociated SNVs that can be used for prediction of ADRs using weighted
genetic risk score (wGRS) models. Therefore, we performed whole-
exome sequencing of gemcitabine/carboplatin treated NSCLC patients
using state of the art high-throughput next-generation sequencing and
association analyses of single-nucleotide variants (SNVs) and genes
with leukopenia and neutropenia. The findings were partially validated
using external GWAS data sets and lastly used for constructing wGRS
prediction models.
2. Materials and methods
An overview of the presented study is illustrated in Fig. 1.
2.1. Study population
Starting in 2006, 215 patients were included, during two con-
secutive years, to the study which was approved by the regional ethics
committee in Stockholm (DNR-0 3-4 13 and DNR-2016/2585-32/1).
Written informed consent was obtained from each patient prior to en-
rollment in accordance with the Helsinki Declaration. The patients were
diagnosed with NSCLC and scheduled for four treatment cycles of
gemcitabine/carboplatin. The included patients received at least one
cycle of gemcitabine (1250 mg/m2) on days 1 and 8, and carboplatin
(AUC = 5) on day 1. Parts of this study population has previously been
described in an extreme-phenotype study [15] and the entire study
population has been used to address genetic variation and thrombo-
cytopenia [16].
2.2. Hematological toxicity
Leukocyte and neutrophil counts were monitored during the first
treatment cycle and recorded at baseline and days 8, 15 and 21. The
severity of leukopenia and neutropenia was measured using the nadir
parameter, defined as the lowest measured blood count on day 8, 14
and 21, and the decrease parameter, defined as baseline adjusted nadir
values (nadir/baseline).
2.3. DNA extraction, exome enrichment and sequencing
QIAamp® DNA mini-kits (VWR International, Stockholm, Sweden)
were used to extract DNA from whole blood according to the manu-
facturer’s protocol. Nextera Rapid Capture Exome kit (Illumina FC-140-
1003, San Diego, USA) was used for target enrichment and library
preparation according to the manufacturer’s instructions. The DNA
samples, 215 in total, were sequenced on Illumina HiSeq 2500 v4 at
Science for Life Laboratory, Stockholm, Sweden.
2.4. Quality control, alignment and variant calling
The sequenced reads were processed using TrimGalore! (http://
www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and cuta-
dapt [17] for quality and adapter trimming, removing reads with Phred
quality score< 25 and pairs with one read length<25. Further data
processing involved Bowtie2 [18] for alignment to reference genome
GRCh37.72, SAMtools [19] for quality filtering, Picard Tools [20] for
duplicate removal and GATK for variant calling applying their best
Fig. 1. Overview over the different steps involved in this
project. First, the included NSCLC patients were whole-exome
sequenced. Genetic variation was analyzed to find leukopenia
and neutropenia associated SNVs and genes. The toxicity as-
sociated SNVs were partially validated with an external GWAS
data set. A prediction model was thereafter set up using vali-
dated SNVs and SNVs located in toxicity associated genes and
applied on the existing data set.
A. Svedberg, et al. Lung Cancer 147 (2020) 106–114
107
practices [21].
2.5. Post variant calling, quality control and outliers
Variants not labeled as PASS, with a genotyping rate< 0.95, with a
mean coverage<10 in all samples and out of Hardy Weinberg
(p<0.0001) were discarded using VCFtools [22].
PLINK was used for detection of outliers [23]. Identity by descent
identified two samples (S0580 and S0664) that contained a large
number of shared variants with the rest of the study population, in-
dicating contamination. Identity by missingness identified two samples
(S0328 and S0664) containing a large number of missing genotypes
probably due to inadequate sequencing. These three samples were re-
moved from the analysis leaving 212 of the 215 samples to remain for
downstream analysis. The three outlier samples also diverged from the
rest of the study population in the number of variants and usable reads,
Supplementary Figure S1.
2.6. Phenotype considerations
The phenotype parameters, nadir and decrease, for leukopenia and
neutropenia were normalized using van der Waerden rank scores im-
plemented in the R package multic [24]. Transformation using natural
logarithm was initially tested but rejected due to the high influence of
one patient with extreme phenotype values.
Initial association analyses with permutations revealed that the
nadir phenotype parameters generated a negligible signal compared to
the background and were therefore not studied further, Supplementary
Figure S2. The association analysis was thereafter only carried out for
for the leukopenia and neutropenia decrease phenotype parameters.
Leukopenia included 212 patients while neutropenia only included 129
patients due to missing baseline values.
2.7. Statistical analysis
Association analysis, adjusted for age and gender, was performed on
SNVs and genes for leukopenia and neutropenia. No influence from
other parameters such as stage or histology were identified. The SNV
association analysis was performed on common SNVs (minor allele
frequency (MAF) ≥ 0.01) in PLINK [23] using an additive genetic
model. A p-value cut-off for indicating suggestive association was set to
≤ 2.2E-04, for leukopenia, and ≤ 1.35E-03, for neutropenia, after
evaluation in PLINK using 1000 permutations to find the most ad-
vantageous false discover rate (FDR) in the p-value interval 0.00001-
0.01, Supplementary Figure S2.
The gene association analysis was performed on all SNVs using
SKATO in the R package SKAT [25,26]. The SNVs were assigned equal
weight otherwise default settings were applied. RefSeq GRCh37/hg19
gene information was obtained from the UCSC table browser [27] and
SNVs were mapped to the corresponding gene (exon region +/- 6
bases) using PLINK [23]. Genes that only contained one rare SNV
(MAF<0.01) were removed from the analysis.
2.8. Validation
2.8.1. Validation data set
GWAS data from Leandro-García et al. (2013) [28] was used as a
validation data set. The study was performed on 144 patients with
European origin homogenously treated with paclitaxel/carboplatin.
The majority of the patients were diagnosed with ovarian (70 %) and
lung cancer (19 %). Leukocyte and neutrophil counts were monitored
throughout the treatment and leukopenia and neutropenia were defined
as time to first toxic event (CTCAE ≥ 1). SNV association analysis,
adjusted for age, was performed with Cox regression using an additive
genetic model in PLINK (version 1.07). The validation data set
(p< 0.005, MAF ≥ 0.01) consisted of 2965 SNVs associated with
leukopenia and 3437 SNVs associated with neutropenia.
2.8.2. Validation method
Validation of SNVs was performed by examining pairwise linkage
disequilibrium (LD) between SNVs of suggestive association in the
presented study population with the SNVs in the validation GWAS data
set using Ensembl REST API (version 6.3). Genotype data originated
from the 1000 Genomes Project Phase 3 and pair-wise LD within a
distance of 500 kb were studied. A European population panel was
selected including CEU (Utah residents with Northern and Western
European ancestry), FIN (Finnish in Finland), GBR (British in England
and Scotland), IBS (Iberian populations in Spain) and TSI (Toscani in
Italy). SNV pairs with a D’ above 0.33 were considered to be in LD and
thereby also support the validity of the SNV pair [29].
2.9. Assembly of prediction models
2.9.1. SNV selection
For SNVs to be included in the wGRS prediction models, the SNVs
were required to be a partially validated SNVs or represented in both
the SNV and gene association analyses. For leukopenia, eight other top
SNVs were additionally included due to that to few eligible SNVs were
otherwise available. In case the SNVs were in LD, only the SNV with the
highest beta value was selected [30].
2.9.2. Weighted genetic risk scores (wGRS)
The toxicity risk prediction model was based on wGRSs created
using the R package PredictABEL [31]. Beta values acquired in the SNV
association analysis were used as weights for the selected SNVs. The
wGRSs were determined by multiplying the beta value with the number
of risk alleles (0, 1 or 2) and then summarized across all included SNVs.
The wGRS were divided into five risk groups based on the distribution
of the wGRS. Risk group 5 was defined as wGRS ≤ (mean wGRS - 1.5
SD), risk group 4 as (mean wGRS – 1.5 SD)<wGRS ≤ (mean wGRS –
0.5 SD), risk group 3 as (mean wGRS – 0.5 SD)<wGRS≤ (mean wGRS
+ 0.5 SD), risk group 2 as (mean wGRS + 0.5 SD)<wGRS ≤ (mean
wGRS + 1.5 SD) and risk group 1 as wGRS> (mean wGRS + 1.5 SD).
Differences in toxicity between the risk groups were determined by
one-way ANOVA followed by Sidak's multiple comparison test using




Patient and toxicity characteristics are outlined in detail in
Supplementary Table S1. The median age of the study population was
64 (45–82) years, with a gender distribution of 53 % females and 47 %
males (confirmed with sex check in PLINK). Tumor stage was dis-
tributed over stages I (18.9 %), II (13.2 %), III (29.7 %), IV (37.3 %) and
not specified (0.9 %). The majority of the patients were diagnosed with
adenocarcinoma (62.3 %) followed by squamous cell carcinoma (18.9
%), unspecified NSCLC (13.7 %), large cell carcinoma (4.7 %) and other
(0.9 %). The highest proportion of the patients were former smokers
(46.7 %) followed by current smokers (43.4 %) and never smokers (9.9
%). Leukopenia and neutropenia were assessed after the first treatment
cycle according to CTCAE v4.03. Leukopenia of CTCAE 0, CTCAE 1–2
and CTCAE 3–4 were identified in 29.7 %, 47.2 % and 23.1 % of the
patients, respectively. Neutropenia of CTCAE 0, CTCAE 1–2 and CTCAE
3–4 were identified in 36.7 %, 13.8 % and 49.5 % of the patients, re-
spectively.
3.2. Sequencing characteristics
For the 215 exome sequenced samples, the average number of
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paired reads was 38.7 million. On average, the mapping yield was 99.2
% and the coverage was 74 X over the target region. The number of
variants saturated around 45 million reads, Supplementary Figure S1.
In the 212 samples, after removal of three outliers (see methods),
149713 filtered variants were identified and of which 71374 variants
were common (MAF ≥ 0.01).
3.3. Genetic association to hematologic toxicity
The SNV association analysis identified 50 and 111 SNVs to be
suggestively associated with leukopenia (p ≤ 2.2E-04, Supplementary
Tables S2) and neutropenia (p ≤ 1.35E-03, Supplementary Tables S3),
respectively. Of these, the top associated SNVs (p ≤ 1E-04) for leuko-
penia and neutropenia are listed in Table 1. The two SNVs, rs10927386
(p = 2.52E-06) and rs10927387 (p = 2.52E-06), with the lowest p-
value associated with leukopenia reside in EFCAB2. Three (p ≤ 4.39E-
05) out of the top four SNVs for neutropenia are in HFM1.
The gene association analysis identified 12 and 20 genes to be
suggestively associated with leukopenia (p ≤ 2.2E-04, Supplementary
Tables S4) and neutropenia (p ≤ 1.35E-03, Supplementary Tables S5),
respectively. Of these the top associated genes (p ≤ 1E-04) for leuko-
penia and neutropenia are listed in Table 2. For leukopenia two genes
were statistically significant after FDR correction for multiple testing,
EFCAB2 (FDR adjusted p = 0.047) and SVIL (FDR adjusted p = 0.047).
The gene EFCAB2 also harbors the two top SNVs, rs10927386 and
rs10927387, identified in the SNV association analysis. The gene SVIL
contains 36 SNVs in the gene association analysis of which four were
also identified in the SNV association analysis with p ≤ 2.2E-04.
3.4. Validation
When comparing the validation GWAS data set with our data set,
112 and 155 SNV pairs within 500 kb were identified for leukopenia
and neutropenia, respectively. LD was confirmed in 38 SNV pairs for
leukopenia and 33 SNV pairs for neutropenia that resulted in partial
validation of 20 unique SNVs for leukopenia and 19 unique SNVs for
neutropenia. All the validated SNVs from our study for leukopenia and
neutropenia and their corresponding GWAS validation SNVs are listed
in Tables 3 and 4, respectively.
The majority of the validated SNVs are located within the genes,
EFCAB2, SVIL, NEK10, SERAC1 and GTPBP1, which were identified in
the gene association analysis for leukopenia. The SNVs rs10927386 and
rs10927387 in EFCAB2 were validated with rs4658733 located in the
neighboring gene KIF26B. In NEK10, rs17854381, rs17680166,
rs1550769, rs1550768, rs11129280 and rs10510592 were validated
with rs11129290 in UBA52P4, rs6768214 in SLC4A7 and rs6774965 in
LOC105377005. The SNV rs6929274 in SERAC1 was validated with
rs1744178, rs1750040 and rs17489570 located in the neighboring gene
SYNJ2. For SVIL, the SNVs rs3740003, rs10160013 and rs1547169
were validated with the GWAS SNVs, rs1624281 and rs1148226, both
also in SVIL.
3.5. Toxicity risk prediction model
Two wGRS toxicity risk prediction models were created, one for
leukopenia including 20 SNVs and one for neutropenia including 28
SNVs, Supplementary Table S6. The wGRSs categorize patients into five
risk groups based on their genetic variation in the model SNVs and their
corresponding beta values as weights. The performance of the models is
illustrated in, Fig. 2A and B, for leukopenia and neutropenia, respec-
tively. Statistically significant differences in toxicity were observed
between all risk groups except between risk group 4 and 5 for neu-
tropenia.
4. Discussion
In the current study, we have shown how genetic variation corre-
lates to leukopenia and neutropenia in NSCLC patients treated with
gemcitabine/carboplatin, Fig. 1. Whole-exome sequencing was per-
formed to identify SNVs, within the coding region of the genome, as-
sociated with chemotherapy-induced hematological toxicity. Genetic
variation associated with leukopenia and neutropenia were studied on
both SNV and gene level. Suggestively associated SNVs were partly
validated with SNVs identified in an independent GWAS data sets by
Table 1
Top associated SNVs for leukopenia and neutropenia (p ≤ 1E-04).
Chr rsID Alleles (ref/alt) Gene symbol Annotation MAFa CADD P-value
Leukopenia 1 rs10927386 T/C EFCAB2 intron 0.3632 7.609 2.52E-06
1 rs10927387 C/T EFCAB2 synonymous 0.3632 15.44 2.52E-06
3 rs17854381 G/A NEK10 synonymous 0.2807 8.163 3.12E-05
3 rs17680166 G/C NEK10 synonymous 0.2759 10.93 3.61E-05
14 rs17128572 C/G GOLGA5 missense 0.1132 24.5 5.17E-05
14 rs17128593 C/G GOLGA5 intron 0.1132 9.083 5.17E-05
18 rs4065379 CTCTG/C DLGAP1-AS1 intron 0.1108 6.561 6.09E-05
14 rs17128583 A/G GOLGA5 synonymous 0.1156 7.938 6.21E-05
22 rs192201349 G/A DMC1 intron 0.01415 3.217 6.25E-05
17 rs79350244 A/C DNAH2 missense 0.03774 24.2 6.28E-05
17 rs117465420 A/T DNAH2 missense 0.03774 19.64 6.28E-05
17 rs117985215 G/A KDM6B intron 0.03774 6.304 6.28E-05
3 rs1550769 C/G NEK10 intron 0.2736 1.164 7.42E-05
3 rs1550768 A/T NEK10 intron 0.2736 1.964 7.42E-05
3 rs11129280 G/T NEK10 synonymous 0.2736 11.98 7.42E-05
3 rs10510592 A/G NEK10 missense 0.2736 9.834 7.42E-05
8 rs7826836 T/G KIAA1456 missense 0.2119 1.595 8.70E-05
Neutropenia 1 rs17131429 G/C HFM1 intron 0.2618 7.811 1.53E-05
2 rs2540923 A/G STRN intron 0.02358 9.572 2.50E-05
1 rs11165778 A/G HFM1 missense 0.2995 0.256 3.49E-05
1 rs281992 T/G HFM1 synonymous 0.3679 11.2 4.39E-05
1 rs1800822 C/T FMO3 synonymous 0.04717 10.34 4.84E-05
19 rs429358 T/C APOE missense 0.1353 0.007 5.11E-05
1 rs10493845 G/A HFM1 synonymous 0.3656 7.491 6.62E-05
19 rs3764605 A/G ATP8B3 synonymous 0.4505 0.005 8.97E-05
Chr, Chromosome; Ref Reference allele; Alt, Alternative Allele; CADD Combined Annotation Dependent Depletion; MAF, Minor allel frequency.
a MAF was calculated within the cohort.
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LD. The obtained result did not indicate that variation in toxicity is due
to one SNV but rather suggested that several SNVs contribute with
small effects. Therefore, the cumulative effect of several genetic var-
iants was merged in wGRSs to create toxicity risk prediction models.
This study included 212 NSCLC patients homogeneously treated
with gemcitabine/carboplatin, which to the best of our knowledge, is
the largest study performed using whole-exome sequencing with drug-
induced leukopenia and neutropenia as primary outcomes.
Leukopenia and neutropenia were monitored at several time points
during the first cycle. The phenotype information for neutropenia was
unfortunately not as comprehensive as for leukopenia. For neutropenia,
the decrease phenotype parameter was only available for 129 patients
since the neutrophil blood counts weren’t routinely analyzed at the time
of the study and the neutrophil count at baseline was therefore easily
missed.
An optimal threshold for indicating suggestive association was de-
termined using permutations for leukopenia and neutropenia to enable
further studies of SNVs since no SNVs reached statistical significance
after correction for multiple testing, Supplementary Figure S2. These
permutation results indicated that the signal from the nadir phenotype
parameters, for both leukopenia and neutropenia, were weak or absent
compared to background noise and therefore the nadir parameters were
excluded from the study. A prominent signal was on the other hand
identified for the leukopenia decrease parameter at the cut-off at p ≤
2.2E-04 (FDR = 28.5 %), which suggest that around 30 of the 50
identified SNVs should be true positives and of relevance for the phe-
notype. An FDR minimum was also observed for the neutropenia de-
crease parameter at p ≤ 1.35E-03 (FDR = 79.5 %) even though not as
pronounced as for leukopenia. Hence, more focus has been directed
towards the leukopenia phenotype as it should contain a larger pro-
portion of true positive SNVs compared to neutropenia.
Despite that the nadir phenotype parameter is frequently used to
assess toxicity during treatment, it might be of advantage to also add
additional information about the initial blood count with the possibility
to enable a more accurate and precise prediction when trying to in-
dividualize treatment before treatment start.
Due to the lack of additional patients in this study, and no previous
whole-exome sequencing studies with a similar research question, we
turned to a currently partly unpublished GWAS that has studied leu-
kopenia and neutropenia in paclitaxel/carboplatin treated NSCLC pa-
tients. The validation data set is not ideal, as the treatment regimens
and technique of retrieving genetic information differs between the
studies. Despite that, our validation approach was to compare LD be-
tween tag-SNPs from the GWAS with the SNVs obtained in our whole-
exome sequencing study. The approach has limitations, for instance, the
SNVs causality cannot be determined, however, the regions identified
in both studies and validated with LD indicate the SNVs importance and
their corresponding genetic regions should be of broad interest to the
research community.
It is worth mentioning that 70 % (14 out of 20 SNVs) of the partially
validated leukopenia associated SNVs reside in genes that were also
found in the gene association analysis. Two of the recurrently identified
genes were SVIL and EFCAB2. They harbor SNVs identified among the
top SNVs in the SNV association analysis, their gene association test
were significant after correction for multiple testing and two SNVs,
rs10927386 and rs10927387, in EFCAB2 and three SNVs, rs3740003,
rs10160013 and rs1547169, in SVIL were also partially validated with
the GWAS data set.
SVIL encodes the peripheral membrane protein supervillin, ex-
pressed for instance in the bone marrow and in neutrophilic lipid rafts
[32,33]. SVIL is known to bind both myosin II and filamentous actin,
and interact with several cytoskeletal proteins [34,35]. The protein
regulates all stages of cell motility and is involved in early cytokinesis
[35]. Knockdown experiments of SVIL have shown to reduce cell divi-
sion and increase cell death in HeLa and U2OS cell lines [36]. This
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could affect the recovery of blood cells after chemotherapy and thereby
also the risk of receiving chemotherapy-induced leukopenia.
In the previous extreme-phenotype study [15], where 32 patients in
this study with extreme phenotypes were participating, rs10160013 in
SVIL was identified to be associated with thrombocytopenia. The SNV
did, however, not pass the validation step. Otherwise, no clear overlap
between the extreme phenotype study and this study was found. Rea-
sons for this could be that different phenotypes and phenotype para-
meters were studied and the previous study only used parts of the pa-
tient material.
The second recurrently identified gene, EFCAB2, has been identified
to be upregulated in zebrafish, Danio rerio, after addition of the tran-
scription factor Ets1-related protein (etsrp) which is required for the
formation of myeloid cells in zebrafish [37,38]. To date, not much is
known about EFCAB2 but the upregulation after etsrp stimulation in-
dicates that it can possess an important role in myelopoiesis.
To utilize the cumulative effect of the several associated SNVs,
wGRS prediction models were created with the intention to, in advance,
be able to predict which patients in risk of receiving severe gemcita-
bine/carboplatin-induced leukopenia or neutropenia, Fig. 2. The
models rely on the ability to categorize the patient into a risk group
based on a set of SNVs in combination with baseline leukocyte and
neutrophil particle count. When the models were applied to our data
the models were able to distinguish between different degrees of leu-
kopenia and neutropenia decrease between the risk groups. Further
validation of these models is, however, desirable to evaluate and vali-
date their performance.
In conclusion, we have in this study identified and partly validated
genetic biomarkers, SNVs and genes, that are associated with gemci-
tabine/carboplatin-induced leukopenia and neutropenia and created
wGRS models for toxicity risk prediction. Of particular interest are the
genes, EFCAB2 and SVIL, since they were identified as significant in the
gene association test and contain several top hits in the SNV association
analysis that were partially validated against the independent GWAS
data set. These results generate solid support for further investigation
into chemotherapy-induced leukopenia and neutropenia. The results
can also be important for other drugs were hematological toxicities are
prominent adverse drug reactions or in other cancers where gemcita-
bine or carboplatin are also used.
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Fig. 2. Weighted genetic risk score (wGRS)
models for leukopenia (A) and neutropenia
(B). The patients are categorized in risk groups
based on their wGRS that is determined based
on the patients genetic variation in 20 and 28
SNVs associated with leukopenia and neu-
tropenia, respectively. Risk group 5 represents
the highest risk group that primarily contain
patients that experienced a large decrease,
having a low percentage of leukocytes and
neutrophils remaining compared to their
baseline levels. The error bars illustrate the
average decrease with 95 % confidence in-
terval (CI) for each risk group. Differences be-
tween the risk groups were analyzed using
ANOVA with Sidak's multiple comparisons test.
Notes: *p<0.05; **p<0.01; ****p< 0.0001.
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